48 results
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new … a workforce reduction of the Company’s workforce of approximately 64% of the Company’s then-current employee base.
2023 FINANCIAL HIGHLIGHTS
Cash
8-K
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
in its workforce by approximately 64% and the termination of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating … knowledge and expertise, attrition beyond the Company’s intended reductions in workforce, a reduction in morale among its remaining employees, and the risk
8-K
EX-99.1
KA
Kineta Inc
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
workforce reduction and the termination of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients … or otherwise determines that other disclosure is necessary or appropriate.
Kineta is reducing its workforce by approximately 64%, which will result
8-K
ildni
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
6vak p04tnv
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
tw59v b3smt
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.3
gy9z lszx4qfv
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
i4cn5uxmfzywm799jc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
u4zl9v
5 Dec 22
Prospectus supplement
9:22am
424B3
zvtxqtz7nu3eqd
10 Nov 22
Prospectus supplement
4:21pm